<DOC>
	<DOC>NCT02184325</DOC>
	<brief_summary>Study to evaluate the tolerability and safety of Kiddi® Pharmaton Fizz effervescent tablets, in children of 6 to 14 years, comparing a given formula with an improved one with reduced mineral content (qualitatively equivalent to the first one) and a comparator product.</brief_summary>
	<brief_title>Safety and Tolerability of Kiddi® Pharmaton Fizz Effervescent Tablets in Children</brief_title>
	<detailed_description />
	<criteria>Children of both sexes aged between 6 and 14 years, inclusive Children, healthy or during convalescence, for which prevention or treatment of marginal vitamin deficits is indicated Willingness of the children and parents to give their written informed consent, according to Good Clinical Practice and local regulations Pregnant children will not be excluded Has taken medications containing vitamins A or D, retinoids, or iron during the 4 weeks preceding the study enrolment Pretreatment (less than 2 weeks prior the inclusion in this trial) and/or concomitant treatment with any drug that may influence the trial symptomatology, and may interfere with the evaluation of the safety of the test drug Participation in other clinical trials within the last 4 weeks and concurrent participation in another clinical trial Relevant allergy or kown hypersensitivity to one of the ingredients of the investigational drug Has any serious disorder that may interfere with the participation to the trial Malabsorption syndrome, liver and/or renal diseases or juvenile diabetes Increased calcium blood concentration, or an increased calciumexcretion Evident states of protein deficiency Presence of lysinemia (defect of the enzyme lysine ketoglutarate reductase)</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>